Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
460
datasets available to search
ShareScore release 0.9.0
Dataset results
460 results for “Immunoglobulin A”
Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in the activated B-cell subtype of diffuse large B-cell lymphoma.
GEO Series GSE119477. Homo sapiens. 8 samples. Type: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing.
Immunoglobulin A controls intestinal virus colonization to preserve immune homeostasis [ZE309]
GEO Series GSE289553. Mus musculus. 88 samples. Type: Expression profiling by high throughput sequencing.
Global gene expression profiles of basophils isolated from human blood after engagement of immunoglobulins on their surface.
GEO Series GSE115296. Homo sapiens. 12 samples. Type: Expression profiling by array.
Allele specific analysis of the immunoglobulin heavy chain locus by simultaneous analysis of the productive and the non-productive allele through paired-end 4C sequencing analysis in mature B cells
GEO Series GSE47128. Mus musculus. 45 samples. Type: Other.
Allele specific analysis of the immunoglobulin heavy chain locus
GEO Series GSE47129. Mus musculus. 57 samples. Type: Expression profiling by array; Other.
The role of basal immunoglobulin signaling in immature B cell development
GEO Series GSE2227. Mus musculus. 49 samples. Type: Expression profiling by array.
Bach2 regulates AID-mediated immunoglobulin gene conversion and somatic hypermutation in DT40 B cells
GEO Series GSE92430. Gallus gallus. 6 samples. Type: Expression profiling by high throughput sequencing.
Immunoglobulin G N-glycan Markers of Accelerated Biological Aging During Chronic HIV Infection
<p>IgG N-glycans dataset</p>
Strategies for Flow Cytometric Profiling of BCR Immunoglobulin Heavy Chain Isotypes: A Comparative Assessment of Fc Receptor Blocking Agents
<p>This study aims to assess the impact of FcR blocking reagents on detection of BCR IgH isotypes IgM, IgD, IgA1-2, and IgG1-4. </p> <p>Blood samples were collected from healthy volunteers in lithium heparin tubes, followed by the isolation of PBMCs utilizing BioColl density gradient centrifugation. The blood samples were diluted at a ratio of 1:1 in PBS with a pH of 7.4 and then centrifuged at 800 g for 20 minutes at RT. The PBMC interphases were harvested and washed three times with PBS containing 2 mM EDTA. Subsequently, PBMCs were resuspended in cRPMI medium. PBMCs were treated with five different FcR blocking reagents prior to staining. For each donor, PBMCs were divided into two groups, with each group containing five samples. One group was stained directly with an immunophenotyping panel without being washed following the application of FCR blocking reagent. The other group was applied washing before staining.<br>Ultimately, the samples were incubated with an 8-color immunophenotyping panel targeting B-cell markers:</p> <table> <tbody> <tr> <td> <p><strong><span>Target</span></strong></p> </td> <td> <p><strong><span>Fluorochrome</span></strong></p> </td> <td> <p><strong><span>Producer</span></strong></p> </td> <td> <p><strong><span>Clone</span></strong></p> </td> <td> <p><strong><span>Isotype</span></strong></p> </td> <td> <p><strong><span>Dilution </span></strong></p> </td> </tr> <tr> <td> <p><span>CD19</span></p> </td> <td> <p><span>APC-eFluor780</span></p> </td> <td> <p><span>eBioscience</span></p> </td> <td> <p><span>HIB19</span></p> </td> <td> <p><span>Mouse, IgG1, kappa</span></p> </td> <td> <p><span>1:100</span></p> </td> </tr> <tr> <td> <p><span>IgM</span></p> </td> <td> <p><span>PerCP/Cy5.5</span></p> </td> <td> <p><span>Biolegend</span></p> </td> <td> <p><span>MHM-88</span></p> </td> <td> <p><span>Mouse, IgG1, kappa</span></p> </td> <td> <p><span>1:100</span></p> </td> </tr> <tr> <td> <p><span>IgD</span></p> </td> <td> <p><span>AF700</span></p> </td> <td> <p><span>Biolegend</span></p> </td> <td> <p><span>IA6-2</span></p> </td> <td> <p><span>Mouse IgG2a, kappa</span></p> </td> <td> <p><span>1:100</span></p> </td> </tr> <tr> <td> <p><span>IgA</span></p> </td> <td> <p><span>VioBlue</span></p> </td> <td> <p><span>Miltenyi</span></p> </td> <td> <p><span>IS11-8E10</span></p> </td> <td> <p><span>Mouse, IgG1, kappa</span></p> </td> <td> <p><span>1:200</span></p> </td> </tr> <tr> <td> <p><span>IgA2</span></p> </td> <td> <p><span>PE</span></p> </td> <td> <p><span>Miltenyi</span></p> </td> <td> <p><span>IS11-21E11</span></p> </td> <td> <p><span>Mouse, IgG1, kappa</span></p> </td> <td> <p><span>1:100</span></p> </td> </tr> <tr> <td> <p><span>IgG1</span></p> </td> <td> <p><span>AF488</span></p> </td> <td> <p><span>AF488/Lumiprobe</span></p> </td> <td> <p><span>MH161-1</span></p> </td> <td> <p><span>Mouse, IgG2b, kappa </span></p> </td> <td> <p><span>1:600</span></p> </td> </tr> <tr> <td> <p><span>IgG1</span></p> </td> <td> <p><span>Dylight550</span></p> </td> <td> <p><span>Dylight/Innova Bio</span></p> </td> <td> <p><span>MH161-1</span></p> </td> <td> <p><span>Mouse, IgG2b, kappa</span></p> </td> <td> <p><span>1:500</span></p> </td> </tr> <tr> <td> <p><span>IgG2</span></p> </td> <td> <p><span>Dylight550</span></p> </td> <td> <p><span>Dylight/Innova Bio</span></p> </td> <td> <p><span>HP6002</span></p> </td> <td> <p><span>Mouse, IgG1, kappa</span></p> </td> <td> <p><span>1:100</span></p> </td> </tr> <tr> <td> <p><span>IgG3</span></p> </td> <td> <p><span>AF488</span></p> </td> <td> <p><span>AF488/Lumiprobe</span></p> </td> <td> <p><span>MH163-1 (HP6095)</span></p> </td> <td> <p><span>Mouse, IgG2b, kappa</span></p> </td> <td> <p><span>1:400</span></p> </td> </tr> <tr> <td> <p><span>IgG4</span></p> </td> <td> <p><span>APC</span></p> </td> <td> <p><span>Cytognos</span></p> </td> <td> <p><span>SAG4</span></p> </td> <td> <p><span>Mouse, IgG1, kappa</span></p> </td> <td> <p><span>1:400</span></p> </td> </tr> <tr> <td> <p><span>CD3</span></p> </td> <td> <p><span>BV605</span></p> </td> <td> <p><span>Biolegend</span></p> </td> <td> <p><span>OKT3</span></p> </td> <td> <p><span>Mouse IgG2a, kappa</span></p> </td> <td> <p><span>1:200</span></p> </td> </tr> <tr> <td> <p><span>CD14</span></p> </td> <td> <p><span>BV605</span></p> </td> <td> <p><span>Biolegend</span></p> </td> <td> <p><span>63D3</span></p> </td> <td> <p><span>Mouse, IgG1, kappa</span></p> </td> <td> <p><span>1:200</span></p> </td> </tr> <tr> <td> <p><span>CD16</span></p> </td> <td> <p><span>BV605</span></p> </td> <td> <p><span>Biolegend</span></p> </td> <td> <p><span>3G8</span></p> </td> <td> <p><span>Mouse, IgG1, kappa</span></p> </td> <td> <p><span>1:200</span></p> </td> </tr> <tr> <td> <p><span>Viability dye</span></p> </td> <td> <p><span>Zombie yellow</span></p> </td> <td> <p><span>Biolegend</span></p> </td> <td> <p><span> </span></p> </td> <td> <p><span> </span></p> </td> <td> <p><span>1:100</span></p> </td> </tr> </tbody> </table> <p>Cells were analyzed on a FACS Aria IIIu (Becton, Dickinson and Company, Franklin Lakes, NJ). B cells were gated as live ZombieYellow-CD3-CD14-CD16-CD19+ lymphocyte. IgM and IgD expression was used to differentiate class-switched (IgM-IgD-) and non-switched (IgM+IgD+) B cells. Next, the IgA+ population, gated from switched B cells, was segregated into IgA1+ (gated as IgA+IgA2-) and IgA2+ (IgA+IgA2+) B cells. The IgA- population was segregated into IgG1+, IgG2+, IgG3+ and IgG4+ B cells. Gates were set based on fluorescence minus one (FMO) controls.<br>To evaluate the effectiveness of the different blocking reagents used in our study on preventing non-specific binding of mouse monoclonal antibodies (mAbs), PBMCs were incubated with isotype control antibodies. Mouse IgG1, IgG2a, and IgG2b antibodies, all conjugated with PE, were evaluated for their non-specific binding to CD14+ monocytes. Prior to staining, the cells were divided into two groups and were treated with FcR blocking reagent as mentioned above. The details concerning the reagents are below:</p> <table> <tbody> <tr> <td> <p><strong><span>Target</span></strong></p> </td> <td> <p><strong><span>Fluorochrome</span></strong></p> </td> <td> <p><strong><span>Brand</span></strong></p> </td> <td> <p><strong><span>Clone</span></strong></p> </td> <td> <p><strong><span>Isotype</span></strong></p> </td> <td> <p><strong><span>Dilution</span></strong></p> </td> </tr> <tr> <td> <p><span>IgG1</span></p> </td> <td> <p><span>PE</span></p> </td> <td> <p><span>Biolegend</span></p> </td> <td> <p><span>MOPC-21</span></p> </td> <td> <p><span>Mouse, IgG1, kappa</span></p> </td> <td> <p><span>1:100</span></p> </td> </tr> <tr> <td> <p><span>IgG2a</span></p> </td> <td> <p><span>PE</span></p> </td> <td> <p><span>Biolegend</span></p> </td> <td> <p><span>MOPC-173</span></p> </td> <td> <p><span>Mouse IgG2a, kappa</span></p> </td> <td> <p><span>1:100</span></p> </td> </tr> <tr> <td> <p><span>IgGb</span></p> </td> <td> <p><span>PE</span></p> </td> <td> <p><span>Biolegend</span></p> </td> <td> <p><span>MPC-11</span></p> </td> <td> <p><span>Mouse, IgG2b, kappa</span></p> </td> <td> <p><span>1:100</span></p> </td> </tr> <tr> <td> <p><span>CD14</span></p> </td> <td> <p><span>BV605</span></p> </td> <td> <p><span>Biolegend</span></p> </td> <td> <p><span>63D3</span></p> </td> <td> <p><span>Mouse, IgG1, kappa</span></p> </td> <td> <p><span>1:200</span></p> </td> </tr> <tr> <td> <p><span>Viability dye</span></p> </td> <td> <p><span>Zombie green</span></p> </td> <td> <p><span>Biolegend</span></p> </td> <td> <p><span> </span></p> </td> <td> <p><span> </span></p> </td> <td> <p><span>1:100</span></p> </td> </tr> </tbody> </table> <p>The analysis of all flow cytometry data was performed using FlowJo v10 software (BD Biosciences). Statistical analysis was conducted using GraphPad Prism 9 software (GraphPad, La Jolla, USA). </p>
Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor
ClinicalTrials.gov study NCT00437463. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Good Use of Normal Human ImmunoGlobulins (NHIg): Feasibility of Integrating the Criteria of Hierarchy During of NHIg Dispensations
ClinicalTrials.gov study NCT06027450. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Intravenous Immunoglobulins for Post-Polio Syndrome
ClinicalTrials.gov study NCT01537575. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Comparing the Efficacy of Anti-secretory Versus Oral Immunoglobulins for Reducing the Episodes of Diarrhea in Children
ClinicalTrials.gov study NCT04885049. IPD Sharing: YES. Countries: 0. Publications: 0.
Assessment of Serum Levels of Adenosine Deaminase and Immunoglobulin E in Patients With Chronic Spontaneous Urticaria
ClinicalTrials.gov study NCT05992987. IPD Sharing: YES. Countries: 0. Publications: 0.
Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia Gravis
ClinicalTrials.gov study NCT00004682. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Randomized Study of Plasmapheresis or Human Immunoglobulin Infusion in Childhood Guillain-Barre Syndrome
ClinicalTrials.gov study NCT00004833. IPD Sharing: Not stated. Countries: 0. Publications: 0.
TREATMENT WITH ANTI-SARS-COV-2 IMMUNOGLOBULIN IN PATIENTS WITH COVID-19
ClinicalTrials.gov study NCT04573855. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Efficacy of Intravenous Immunoglobulin in Management of Rh and ABO Incompatibility Disease
ClinicalTrials.gov study NCT03130517. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Randomized Study of Intravenous Immunoglobulin (IVIg) in Patients With Subacute Proximal Diabetic Neuropathy
ClinicalTrials.gov study NCT00004407. IPD Sharing: Not stated. Countries: 0. Publications: 0.
The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia
ClinicalTrials.gov study NCT04261426. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.